CIRSE Insider

Dr. Tomohiro Matsumoto (Nankoku/JP) et al. were awarded this year’s Magna Cum Laude Poster Award for their research on N-Butyl Cyanoacrylate versus Coils for Transcatheter Arterial Embolization in Lower Gastrointestinal Bleeding: A Nationwide Study.

CIRSE Insider: Can you tell us briefly about your medical and academic background? How involved are you in embolization procedures (including those for GI bleeding) at your medical centre?

Matsumoto: My training began at Kyoto Prefectural University of Medicine under Dr. Takuji Yamagami, who is now Professor of Diagnostic and Interventional Radiology at Kochi University. He was the person who first introduced me to interventional radiology. I later joined Tokai University, where I had the opportunity to work with Prof. Terumitsu Hasebe. There, I was involved not only in clinical interventional radiology, but also in biomedical engineering and translational research. Now, I serve as Associate Professor of Diagnostic and Interventional Radiology at Kochi University. At our institution, I am actively involved in a wide range of embolization procedures, including the management of GI bleeding, haemoptysis, and iatrogenic haemorrhage. GI bleeding is one of the major indications for emergency embolization in our daily practice, and I have been involved in the treatment of these patients throughout my career.

CIRSE Insider: Your research compares the efficacy of two embolization methods— N-butyl cyanoacrylate (NBCA) and coils— for lower GI bleeding. What led you to investigate this topic?

Matsumoto: The optimal embolic agent for lower GI bleeding remains a matter of debate. Concerns about ischemic complications and variability in reported clinical outcomes have made it difficult to determine whether one embolic material is truly superior to another. At the same time, most published studies have been relatively small and conducted at single centres. As an interventional radiologist, I felt that a nationwide real-world analysis could provide a broader perspective on how these embolic agents perform in routine clinical practice.

CIRSE Insider: Why did you specifically choose to compare NBCA with coils?

Matsumoto: They have very different characteristics. NBCA provides rapid and permanent occlusion and may be particularly useful in patients with coagulopathy or small target vessels. In contrast, coils allow precise mechanical embolization but may be less effective in certain clinical situations, such as severe coagulopathy or vasopressor-dependent states. Given these differences, we felt that comparing their real-world outcomes would be clinically meaningful.

CIRSE Insider: What were the key findings of your study? How do you see these findings impacting care for patients with GI bleeding?

Matsumoto: Our study suggests that short-term outcomes after TAE for lower GI bleeding are driven primarily by patient-related clinical severity rather than the embolic material. That said, NBCA may still be considered in situations requiring rapid haemostasis or when distal catheterization is difficult. Importantly, because NBCA is a liquid embolic agent that requires specific technical skills, structured education and training are essential for its safe and effective use.

CIRSE Insider: Why did you choose to submit your findings to ET 2026?

Matsumoto: ET is one of the leading international meetings dedicated to embolization. Since our study focused on the clinical outcomes of different embolic materials in lower GI bleeding, we felt that ET was the ideal venue to share our findings with physicians who perform embolization procedures in daily practice.

CIRSE Insider: Do you have any plans for further research on embolization topics?

Matsumoto: That’s a bit top secret for now! However, I can share a little about our future direction. I plan to continue conducting real-world data research on embolization topics. I also believe that real-world data research and artificial intelligence are excellent partners. By combining large-scale healthcare data with AI-based approaches, I hope to gain deeper insights into patient outcomes and support more evidence-based clinical decision-making.

CIRSE Insider: Anything else you’d like to mention?

Matsumoto: Thank you very much for this wonderful honour. I am truly delighted to receive the Magna Cum Laude poster award at ET 2026. I would also like to thank my colleagues and collaborators who contributed to this work. I look forward to future opportunities to participate in CIRSE activities and to continuing international collaboration in interventional radiology.

Dr. Tomohiro Matsumoto (Nankoku/JP) et al. were awarded this year’s Magna Cum Laude Poster Award for their research on N-Butyl Cyanoacrylate versus Coils for Transcatheter Arterial Embolization in Lower Gastrointestinal Bleeding: A Nationwide Study.

CIRSE Insider: Can you tell us briefly about your medical and academic background? How involved are you in embolization procedures (including those for GI bleeding) at your medical centre?

Matsumoto: My training began at Kyoto Prefectural University of Medicine under Dr. Takuji Yamagami, who is now Professor of Diagnostic and Interventional Radiology at Kochi University. He was the person who first introduced me to interventional radiology. I later joined Tokai University, where I had the opportunity to work with Prof. Terumitsu Hasebe. There, I was involved not only in clinical interventional radiology, but also in biomedical engineering and translational research. Now, I serve as Associate Professor of Diagnostic and Interventional Radiology at Kochi University. At our institution, I am actively involved in a wide range of embolization procedures, including the management of GI bleeding, haemoptysis, and iatrogenic haemorrhage. GI bleeding is one of the major indications for emergency embolization in our daily practice, and I have been involved in the treatment of these patients throughout my career.

CIRSE Insider: Your research compares the efficacy of two embolization methods— N-butyl cyanoacrylate (NBCA) and coils— for lower GI bleeding. What led you to investigate this topic?

Matsumoto: The optimal embolic agent for lower GI bleeding remains a matter of debate. Concerns about ischemic complications and variability in reported clinical outcomes have made it difficult to determine whether one embolic material is truly superior to another. At the same time, most published studies have been relatively small and conducted at single centres. As an interventional radiologist, I felt that a nationwide real-world analysis could provide a broader perspective on how these embolic agents perform in routine clinical practice.

CIRSE Insider: Why did you specifically choose to compare NBCA with coils?

Matsumoto: They have very different characteristics. NBCA provides rapid and permanent occlusion and may be particularly useful in patients with coagulopathy or small target vessels. In contrast, coils allow precise mechanical embolization but may be less effective in certain clinical situations, such as severe coagulopathy or vasopressor-dependent states. Given these differences, we felt that comparing their real-world outcomes would be clinically meaningful.

CIRSE Insider: What were the key findings of your study? How do you see these findings impacting care for patients with GI bleeding?

Matsumoto: Our study suggests that short-term outcomes after TAE for lower GI bleeding are driven primarily by patient-related clinical severity rather than the embolic material. That said, NBCA may still be considered in situations requiring rapid haemostasis or when distal catheterization is difficult. Importantly, because NBCA is a liquid embolic agent that requires specific technical skills, structured education and training are essential for its safe and effective use.

CIRSE Insider: Why did you choose to submit your findings to ET 2026?

Matsumoto: ET is one of the leading international meetings dedicated to embolization. Since our study focused on the clinical outcomes of different embolic materials in lower GI bleeding, we felt that ET was the ideal venue to share our findings with physicians who perform embolization procedures in daily practice.

CIRSE Insider: Do you have any plans for further research on embolization topics?

Matsumoto: That’s a bit top secret for now! However, I can share a little about our future direction. I plan to continue conducting real-world data research on embolization topics. I also believe that real-world data research and artificial intelligence are excellent partners. By combining large-scale healthcare data with AI-based approaches, I hope to gain deeper insights into patient outcomes and support more evidence-based clinical decision-making.

CIRSE Insider: Anything else you’d like to mention?

Matsumoto: Thank you very much for this wonderful honour. I am truly delighted to receive the Magna Cum Laude poster award at ET 2026. I would also like to thank my colleagues and collaborators who contributed to this work. I look forward to future opportunities to participate in CIRSE activities and to continuing international collaboration in interventional radiology.

Dr. Tomohiro Matsumoto (Nankoku/JP) et al. were awarded this year’s Magna Cum Laude Poster Award for their research on N-Butyl Cyanoacrylate versus Coils for Transcatheter Arterial Embolization in Lower Gastrointestinal Bleeding: A Nationwide Study.

CIRSE Insider: Can you tell us briefly about your medical and academic background? How involved are you in embolization procedures (including those for GI bleeding) at your medical centre?

Matsumoto: My training began at Kyoto Prefectural University of Medicine under Dr. Takuji Yamagami, who is now Professor of Diagnostic and Interventional Radiology at Kochi University. He was the person who first introduced me to interventional radiology. I later joined Tokai University, where I had the opportunity to work with Prof. Terumitsu Hasebe. There, I was involved not only in clinical interventional radiology, but also in biomedical engineering and translational research. Now, I serve as Associate Professor of Diagnostic and Interventional Radiology at Kochi University. At our institution, I am actively involved in a wide range of embolization procedures, including the management of GI bleeding, haemoptysis, and iatrogenic haemorrhage. GI bleeding is one of the major indications for emergency embolization in our daily practice, and I have been involved in the treatment of these patients throughout my career.

CIRSE Insider: Your research compares the efficacy of two embolization methods— N-butyl cyanoacrylate (NBCA) and coils— for lower GI bleeding. What led you to investigate this topic?

Matsumoto: The optimal embolic agent for lower GI bleeding remains a matter of debate. Concerns about ischemic complications and variability in reported clinical outcomes have made it difficult to determine whether one embolic material is truly superior to another. At the same time, most published studies have been relatively small and conducted at single centres. As an interventional radiologist, I felt that a nationwide real-world analysis could provide a broader perspective on how these embolic agents perform in routine clinical practice.

CIRSE Insider: Why did you specifically choose to compare NBCA with coils?

Matsumoto: They have very different characteristics. NBCA provides rapid and permanent occlusion and may be particularly useful in patients with coagulopathy or small target vessels. In contrast, coils allow precise mechanical embolization but may be less effective in certain clinical situations, such as severe coagulopathy or vasopressor-dependent states. Given these differences, we felt that comparing their real-world outcomes would be clinically meaningful.

CIRSE Insider: What were the key findings of your study? How do you see these findings impacting care for patients with GI bleeding?

Matsumoto: Our study suggests that short-term outcomes after TAE for lower GI bleeding are driven primarily by patient-related clinical severity rather than the embolic material. That said, NBCA may still be considered in situations requiring rapid haemostasis or when distal catheterization is difficult. Importantly, because NBCA is a liquid embolic agent that requires specific technical skills, structured education and training are essential for its safe and effective use.

CIRSE Insider: Why did you choose to submit your findings to ET 2026?

Matsumoto: ET is one of the leading international meetings dedicated to embolization. Since our study focused on the clinical outcomes of different embolic materials in lower GI bleeding, we felt that ET was the ideal venue to share our findings with physicians who perform embolization procedures in daily practice.

CIRSE Insider: Do you have any plans for further research on embolization topics?

Matsumoto: That’s a bit top secret for now! However, I can share a little about our future direction. I plan to continue conducting real-world data research on embolization topics. I also believe that real-world data research and artificial intelligence are excellent partners. By combining large-scale healthcare data with AI-based approaches, I hope to gain deeper insights into patient outcomes and support more evidence-based clinical decision-making.

CIRSE Insider: Anything else you’d like to mention?

Matsumoto: Thank you very much for this wonderful honour. I am truly delighted to receive the Magna Cum Laude poster award at ET 2026. I would also like to thank my colleagues and collaborators who contributed to this work. I look forward to future opportunities to participate in CIRSE activities and to continuing international collaboration in interventional radiology.